Abstract
In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.
| Original language | English |
|---|---|
| Pages (from-to) | 627-640 |
| Number of pages | 14 |
| Journal | Japanese Journal of Chemotherapy |
| Volume | 53 |
| Issue number | 10 |
| Publication status | Published - Oct 2005 |
Fingerprint
Keywords
- Fluoroquinolone
- Gatifloxacin
- Surveillance
ASJC Scopus subject areas
- Pharmacology
Cite this
Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. / Yamaguchi, Keizo; Furuya, Nobuhiko; Iwata, Morihiro; Watanabe, Naoki; Uehara, Nobuyuki; Yasujima, Minoru; Kasai, Takeshi; Kaku, Mitsuo; Abe, Yuko; Igari, Jun; Oguri, Toyoko; Baba, Hisashi; Yoshimura, Hitoshi; Yamanaka, Kiyoharu; Ischiyama, Satoshi; Kusano, Nobuchika; Murao, Naoko; Ono, Junko; Tou, Hiromi; Okada, Kaoru; Ishida, Masami; Hirakata, Yoichi; Matsuda, Junichi.
In: Japanese Journal of Chemotherapy, Vol. 53, No. 10, 10.2005, p. 627-640.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents
AU - Yamaguchi, Keizo
AU - Furuya, Nobuhiko
AU - Iwata, Morihiro
AU - Watanabe, Naoki
AU - Uehara, Nobuyuki
AU - Yasujima, Minoru
AU - Kasai, Takeshi
AU - Kaku, Mitsuo
AU - Abe, Yuko
AU - Igari, Jun
AU - Oguri, Toyoko
AU - Baba, Hisashi
AU - Yoshimura, Hitoshi
AU - Yamanaka, Kiyoharu
AU - Ischiyama, Satoshi
AU - Kusano, Nobuchika
AU - Murao, Naoko
AU - Ono, Junko
AU - Tou, Hiromi
AU - Okada, Kaoru
AU - Ishida, Masami
AU - Hirakata, Yoichi
AU - Matsuda, Junichi
PY - 2005/10
Y1 - 2005/10
N2 - In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.
AB - In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.
KW - Fluoroquinolone
KW - Gatifloxacin
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=28444471310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28444471310&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:28444471310
VL - 53
SP - 627
EP - 640
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 10
ER -